Edotreotide
Gallium Ga Edotreotide, SomaKit TOC (edotreotide) is a small molecule pharmaceutical. Edotreotide was first approved as Somakit toc on 2016-12-08. It has been approved in Europe to treat neuroendocrine tumors and radionuclide imaging. It is known to target somatostatin receptor type 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ga-68-dotatoc | New Drug Application | 2021-12-08 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
GALLIUM GA-68 EDOTREOTIDE, GALLIUM GA 68 EDOTREOTIDE, UIHC PET IMAGING | |||
| 2026-08-21 | ODE-383, W | ||
| 2024-08-21 | NCE, W | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
75 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 13 | 18 | 6 | — | 16 | 49 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 3 | 1 | — | — | 5 |
| Lung neoplasms | D008175 | — | C34.90 | 1 | 1 | 1 | — | — | 3 |
| Pituitary neoplasms | D010911 | — | — | — | — | 1 | — | 1 | 2 |
| Glioma | D005910 | EFO_0000520 | — | — | 1 | 1 | — | 1 | 2 |
| Pituitary diseases | D010900 | — | E23.7 | — | — | 1 | — | — | 1 |
| Thymus neoplasms | D013953 | — | C37 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoid tumor | D002276 | — | D3A.00 | 5 | 6 | — | — | 4 | 13 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 4 | 7 | — | — | 3 | 12 |
| Meningioma | D008579 | EFO_0003098 | D32.9 | 4 | 6 | — | — | 3 | 11 |
| Neoplasms | D009369 | — | C80 | 6 | 3 | — | — | 1 | 9 |
| Medulloblastoma | D008527 | — | — | 1 | 5 | — | — | 2 | 7 |
| Paraganglioma | D010235 | — | — | 2 | 4 | — | — | 3 | 7 |
| Pheochromocytoma | D010673 | — | — | 2 | 3 | — | — | 2 | 6 |
| Islet cell adenoma | D007516 | EFO_0007331 | D13.7 | 2 | 1 | — | — | 1 | 4 |
| Prostatic neoplasms | D011471 | — | C61 | — | 2 | — | — | 1 | 3 |
| Lymphoma | D008223 | — | C85.9 | 2 | 1 | — | — | — | 3 |
Show 15 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Central nervous system neoplasms | D016543 | — | — | 3 | — | — | — | — | 3 |
| Ganglioneuroma | D005729 | — | — | 1 | — | — | — | 1 | 2 |
| Endocrine gland neoplasms | D004701 | EFO_0003769 | D35 | 1 | — | — | — | 1 | 2 |
| Primitive neuroectodermal tumors peripheral | D018241 | — | — | 1 | — | — | — | 1 | 2 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | 2 | — | — | — | — | 2 |
| Nervous system neoplasms | D009423 | — | — | 2 | — | — | — | — | 2 |
| Malignant carcinoid syndrome | D008303 | — | E34.0 | 2 | — | — | — | — | 2 |
| Von hippel-lindau disease | D006623 | — | Q85.83 | 1 | — | — | — | — | 1 |
| Multiple endocrine neoplasia type 1 | D018761 | — | E31.21 | 1 | — | — | — | — | 1 |
| Multiple endocrine neoplasia | D009377 | — | E31.2 | 1 | — | — | — | — | 1 |
Show 6 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | — | — | — | 3 | 3 |
| Medullary carcinoma | D018276 | — | — | — | — | — | — | 2 | 2 |
| Intestinal neoplasms | D007414 | — | C26.0 | — | — | — | — | 2 | 2 |
| Small cell lung carcinoma | D055752 | — | — | — | — | — | — | 1 | 1 |
| Brain stem neoplasms | D020295 | EFO_1001767 | — | — | — | — | — | 1 | 1 |
| Glucagonoma | D005935 | — | — | — | — | — | — | 1 | 1 |
| Myocarditis | D009205 | — | I51.4 | — | — | — | — | 1 | 1 |
| Recurrence | D012008 | — | — | — | — | — | — | 1 | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | — | — | 1 | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | — | — | — | — | 1 | 1 |
Show 28 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Edotreotide |
| INN | edotreotide |
| Description | Edotreotide (USAN, also known as (DOTA0-Phe1-Tyr3) octreotide, DOTA-TOC, DOTATOC) is a substance which, when bound to various radionuclides, is used in the treatment and diagnosis of certain types of cancer. When used therapeutically it is an example of peptide receptor radionuclide therapy.
|
| Classification | Small molecule |
| Drug class | peptides: inhibition of growth hormone release |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O |
Identifiers
| PDB | — |
| CAS-ID | 173606-11-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL408350 |
| ChEBI ID | — |
| PubChem CID | 158782 |
| DrugBank | DB15494 |
| UNII ID | U194AS08HZ (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,877 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
18 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use